高级检索
当前位置: 首页 > 详情页

Generation and characterization of a IgG monoclonal antibody specific for GM3 (NeuGc) ganglioside by immunizing beta 3Gn-T5 knockout mice

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 4, Dept Clin Biocell, Shijiazhuang 050000, Hebei, Peoples R China [2]Hebei Gen Hosp, Dept Oncol, Shijiazhuang 050000, Hebei, Peoples R China [3]Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Hangzhou 310053, Zhejiang, Peoples R China [4]Hebei Gen Hosp, Dept Nursing, Shijiazhuang 050000, Hebei, Peoples R China [5]Hebei Med Univ, Hosp 4, Res Ctr, Shijiazhuang 050000, Hebei, Peoples R China [6]Hebei Gen Hosp, Dept Pathol, Shijiazhuang 050000, Hebei, Peoples R China [7]Zhejiang Chinese Med Univ, Lab & Equipment Adm, Hangzhou 310053, Zhejiang, Peoples R China
出处:
ISSN:

摘要:
A murine monoclonal antibody (MAb-1) specific for GM3 has been generated by immunizing beta 3Gn-T5 knockout mice with purified GM3 ganglioside. The binding specificity of MAb-1 (IgG(3) subclass) was established by an enzyme-linked immunosorbent assay (ELISA) and FACS and the antibody showed high binding specificity with GM3. Cell viability assay showed that MAb-1 significantly suppressed cell growth. Immunohistochemistry analysis revealed that MAb-1 was strongly expressed in human ovarian cancer tissues, whereas it was hardly expressed in normal tissues. Finally, antibody-dependent cellular cytotoxicity (ADCC) activities were determined by measuring lactate dehydrogenase (LDH) releasing assay and the results showed high ADCC activities in two representative ovarian cancer cell lines (OVHM and ID8). All of these data indicate that MAb-1 may be potentially used as a therapeutic antibody against ovarian cancers in clinical trials.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2018]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
最新[2025]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
JCR分区:
出版当年[2018]版:
Q1 MULTIDISCIPLINARY SCIENCES
最新[2024]版:
Q1 MULTIDISCIPLINARY SCIENCES

影响因子: 最新[2024版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 4, Dept Clin Biocell, Shijiazhuang 050000, Hebei, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号